<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Otecon-------------------------------------------------------->
<div class="bodyDiv" id="idOtecon">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Otecon</h2>
    </div>
<b>Product Orientation & Presentation:</b><br>

<b>Brand Name:</b><br>
Otecon
<br><br>

<b>Generic & Strength:</b><br>
Oteseconazole INN 150 mg
<br><br>
	
<b>Dosage Form:</b><br>
Capsule.
<br><br>
	
<b>Therapeutic Class:</b><br>
 Antifungal
<br><br>

<b>Sub Therapeutic class:</b><br>
<br><br>

<b>Commercial Pack:</b><br>
10's
<br><br>

<b>Price(MRP):</b><br>
190.00 Bdt/ Capsule
<br><br>

<b>Flavour:</b><br>
<br><br>

<b>Indication:</b><br>
Otecon is an azole antifungal indicated for the management of recurrent vulvovaginal candidiasis (RVVC) in
females with a history of RVVC and who are NOT of reproductive potential.
<br><br>

<b>Dosage & Administration:</b><br>
There are two dosage regimens of Oteseconazole:<br>
<u>1) Otecon only regimen:</u><br>

On 1<sup>st</sup> day:<br>
Otecon 600 mg (4 capsules as a single dose) needs to be administered,<br>
then, On 2<sup>nd</sup> day:<br>
Otecon 450 mg (3 capsules as a single dose) needs to be administered,<br>
then, On 14<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once a week for 11 weeks (2<sup>nd</sup> to <sup>12</sup> week).<br>

<u>2) Fluconazole and Otecon regimen:</u><br>
On 1<sup>st</sup>, 4<sup>th</sup>, and 7<sup>th</sup> day:<br>
Fluconazole 150 mg needs to be administered orally,<br>
then, On 14<sup>th</sup> to 20<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once daily for 7 days,<br>
then, On 28<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once a week for 11 weeks (4<sup>th</sup> to 14<sup>th</sup> week).<br>
Otecon should be administered orally with food or as directed by the physician.
<br><br>

<b>Pregnancy:</b><br>
Oteseconazole is contraindicated in females of reproductive potential and in pregnant women. Based on animal studies,
Oteseconazole may cause fetal harm when administered to pregnant women.
<br><br>

<b>Lactation:</b><br>
Oteseconazole is contraindicated
Otecon in lactating women. There are no data on the presence of Oteseconazole in human or animal milk or
data on the effects of Oteseconazole on milk production. There Otecon were no reported adverse effects
in breastfed infants following maternal exposure to Oteseconazole during lactation.
<br><br>

<b>Children:</b><br>
The safety and effectiveness of Otes econazole have not been established in pre-menarchal paediatric females.
<br><br>

<b>Brand Name Justification:</b><br>
<b>Ote</b>se<b>con</b>azole<br>
= Otecon
<br><br>

<b>Brand Slogan:</b><br>
The only FDA-approved drug to treat RVVC
<br><br>

<b>Key Selling Points:</b><br>
* The only FDA-approved drug to treat RVVC.<br>
* Provides a comfortable life to our beloved ones.<br>
* Ensures less side effects & offers patient safety.<br>
* Beats the azole-resistant fungal infections.
<br><br>

<b>Target Doctor:</b><br>
Gynecologist<br>
Selected Medicine Specialists
<br>

<b>Objective:</b><br>
<br><br>

<b>Action:</b><br>
<br><br>

<b>Side effects:</b><br>
The most frequently reported side effects were headache and nausea, which were found in less than 2% of patients.
<br><br>

<b>Contraindication:</b><br>
Oteseconazole is contraindicated in patients with known history of hypersensitivity to it,
pregnant and lactating women as well as females of reproductive potential.
<br><br>

<b>Precautions and warnings:</b><br>
Embryo-Fetal Toxicity:<br>
Based on animal studies, Otes econazole may cause fetal harm. Patients must be advised that Oteseconazole
is contraindicated in females of reproductive potential, and in pregnant and lactating women.
<br><br>

<b>Interaction:</b><br>
<br><br>

<b><u>Mechanism of action</u></b><br>
<table class="table6">
    <tr>
        <td>Oteseconazole
        </td>
    </tr>
    <tr>
        <td>
            <b>&#8681;</b>
        </td>
    </tr>
    <tr>
        <td>
            Inhibits fungal CYP51 with high selectivity
        </td>
    </tr>
    <tr>
        <td>
            <b>&#8681;</b>
        </td>
    </tr>
    <tr>
        <td>
            Inhibits ergosterol production
        </td>
    </tr>
    <tr>
        <td>
            <b>&#8681;</b>
        </td>
    </tr>
    <tr>
        <td>
            Inhibits fungal cell membrane synthesis
        </td>
    </tr>
</table>
<br><br>

CDC defines RVVC (Recurrent Vulvovaginal Candidiasis) as the VVC that occurs at 3 to more symptomatic episodes in a year. Conventional antifungals such as Fluconazole & Voriconazole were found in study to be resistant by 34% & 14% respectively against Candida albicans, a common pathogen for RVVC. So, VVC relapses, leaving the patients in endless discomfort. Unfortunately, before Oteseconazole gets approved, no FDA-approved drug was available.<br>
<i>It is Oteseconazole that is the first FDA-approved drug for RVVC.
</i><br>
NAVANA introduces<br>
<b>Otecon</b><br>
Oteseconazole INN 150 mg Capsule<br>
The only FDA-approved drug to treat RVVC<br><br>

<b>Demonstrates significant activity against most RVVC causing microorganisms.</b><br>
% of women being recurrence-free for up to 1 year.<br>
Study Period: 48 Weeks<br>
        Study Population: 330<br>
96.1% Oteseconazole<br>
42.9% Fluconazole<br>
<i>Prevents recurrence in more than 96% cases.</i><br>
<i>*Provides a comfortable life to our beloved ones.</i><br><br>

<b>Shows the greatest affinity for fungal CYP51 than for human's</b><br>
2200 folds Oteseconazole<br>
540 folds Fluconazole(Separate study)<br>
92 folds Voriconazole(Same study)<br>
<i>*Ensures less side effects & offers patient safety.</i><br><br>

<b>Exhibits the highest potency among all antifungals against most common pathogens for RVVC.</b><br>
<u>Potency against Candida albicans:</u><br>
63 folds more potent than Fluconazole<br>
31 folds more potent than Voriconazole.<br><br>

<u>Potency against Candida glabrata:</u><br>
67 folds more potent than Fluconazole<br>
17 folds more potent than Voriconazole<br>

<i>*Beats the azole-resistant fungal infections.</i><br><br>

* The only FDA-approved drug to treat RVVC.<br>
* Provides a comfortable life to our beloved ones.<br>
* Ensures less side effects & offers patient safety.<br>
* Beats the azole-resistant fungal infections.<br>

<u><b>Oteseconazole is contraindicated in females of reproductive
    potential, pregnant and lactating women.</b></u><br><br>


Dosage guideline<br>
Day 1 : 4 capsules together<br>
Day 2 : 3 capsules together<br>
Day 14:1 capsule weekly for 11 weeks<br>
Should be taken orally with food<br><br>

Otecon Detail Talk<br>
ম্যাডাম/স্যার,<br>

আসসালামু আলাইকুম। আজ আপনার সাথে এমন একটি নতুন Drug এর তথ্য share করতে চাই, যেটি Recurrent Vulvovaginal Candidiasis (RVVC) এর treatment এ প্রথম FDA - approved & recommended drug. জীবনের শেষ ভাগে এসে প্রতিটি নারীই চান যে তার বাকিটা সময় শান্তিতে কাটুক। কিন্তু এই RVVC, post-menopausal women দের জন্য একটি অভিশাপের মতো, যা তাদের শুধু শারীরিকভাবেই নয়, মানসিকভাবেও বিপর্যস্ত করে।<br>

তখন প্রশ্ন থেকেই যায় যে, এই RVVC এর যন্ত্রণা থেকে কি কখনও মুক্তি মিলবে না?<br>

RVVCIT FDA-approved & recommended treatment option না থাকায় সাধারণত Fluconazole & Voriconazole দিয়ে treatment করা হয়। একটি Global study তে পাওয়া গিয়েছে RVVC এর অন্যতম প্ৰধান কারণ Candida albians (ক্যানডিডা অ্যালবিক্যানস) এর against এ Fluconazole 34% এবং Voriconazole 14% resistance হয়ে গিয়েছে। যার rate বাংলাদেশের ক্ষেত্রে আরও বেশি হতে পারে। Fluconazole & Voriconazole poor efficacy, growing fungal resistance অধিকাংশ ক্ষেত্রেই RVVC পুনরায় ফিরে আসে। যা একজন post - menopausal woman এর জীবন আরও দুর্বিষহ করে তোলে।<br>

Post-menopausal women দের RVVC নামক এই দুর্বিষহ যন্ত্রণা থেকে মুক্তি দিতে Navana Pharma নিয়ে এসেছে, Otecon- ওটিকন (Oteseconazole - ওটিসিকোনাজল) 150 mg Capsule যা RVVC এর জন্য FDA থেকে একমাত্র approval পাওয়া drug.<br>

Oteseconazole fungal CYP51 enzyme কে inhibit করার মাধ্যমে ergosterol production বন্ধ করে, যার ফলে fungal cell membrane synthesis হতে পারে না।<br>

Clinical trial এর study তে দেখা গিয়েছে, Otecon (Oteseconazole) ব্যবহারে 96% patients এর ক্ষেত্রে 1 year পর্যন্ত RVVC এর কোনো recurrence ঘটে নি, যেখানে Fluconazole এর success rate only 42.9%.<br>

Otecon (Oteseconazole) এর human এর CYP51 এর তুলনায় fungal CYP51 এর প্রতি affinity প্রায় 2200 গুন। যার কারনে Otecon এর side effects Fluconazole এবং Voriconazole থেকে অনেক কম।<br>

এছাড়াও RVVC এর major দুটি pathogen, Candida albicans (ক্যানডিডা অ্যালবিক্যানস) এবং Candida glabrata (ক্যানডিডা গ্লাব্রাটা) এর against এ Oteseconazole এর potency Fluconazole এবং Voriconazole এর চেয়ে বেশি।<br>

Candida albicans এর against এ Oteseconazole, Fluconazole থেকে 63 গুন এবং Voriconazole থেকে 31 গুন বেশি potent.<br>

Candida glabrata 4 against 4 Oteseconazole, Fluconazole থেকে 67 গুন এবং Voriconazole থেকে 17 গুন বেশি potent.<br>

ম্যাডাম/স্যার, Otecon এর features গুলো যদি একটু summary করে বলতে চাই<br>

* The only FDA-approved drug to treat RVVC.<br>

* Provides a comfortable life to our beloved ones.<br>

* Ensures less side effects & offers patient safety.<br>

* Beats the azole-resistant fungal infections.<br>

সর্বোপরি, RVVC এর জন্য এতোদিন যে effective & approved treatment option এর অভাব ছিলো, সেটি দূর করেছে এই Oteseconazole.<br>
আমরা আশা করি, এই drug টি post-menopausal women দের RVVC এর treatment এ আশার আলো হবে।<br>

Oteseconazole drug টি সন্তান জন্মদানে সক্ষম, pregnant এবং lactating women contraindicated.<br>

Otecon এর dosage guideline অনুযায়ী,<br>

১ম দিন ০৪ টি ক্যাপসুল একসাথে,<br>

২য় দিন ০৩ টি ক্যাপসুল একসাথে,<br>

১৪ তম দিন ১ টি ক্যাপসুল,<br>

এরপর প্রতি সপ্তাহে ০১ টি ক্যাপসুল ভরাপেটে ১০ সপ্তাহ খেতে হবে। অর্থাৎ ১২ সপ্তাহে সর্বমোট ১৮ টি ক্যাপসুলের কোর্স সম্পন্ন করতে হবে।<br>

আপনাকে অনুরোধ করবো, Post-menopausal women দের RVVC এর treatment এ Otecon prescribe করার জন্য।<br>

Thank you Madam / Sir for your time.<br><br>


<b>Prescribing Information:</b><br>

<b>Composition:</b><br>

Otecon Capsule: Each capsule contains Otes econazole INN 150 mg.<br>

<b>Pharmacology:</b><br>
Oteseconazole is an azole metalloenzyme inhibitor targeting the fungal sterol, 14 &alpha; demethylase (CYP51), an enzyme that catalyzes an early step in the biosynthetic pathway of ergosterol. Ergosterol is required for fungal cell
membrane formation and integrity. Inhibition of CYP51 results in the accumulation of 14-methylated sterols, some of which are toxic to fungi. Through the inclusion
of a tetrazole metal-binding group, Oteseconazole has a lower affinity for human CYP enzymes.<br>

<b>Indications:</b><br>
Otecon is an azole antifungal indicated for the management of recurrent vulvovaginal
candidiasis (RVVC) in females with a history of RVVC and who are NOT of reproductive potential.<br>

<b>Dosage and Administration:</b><br>

There are two dosage regimens of Oteseconazole:<br>
<u>1) Otecon only regimen:</u><br>

On 1<sup>st</sup> day:<br>
Otecon 600 mg (4 capsules as a single dose) needs to be administered,<br>
then, On 2<sup>nd</sup> day:<br>
Otecon 450 mg (3 capsules as a single dose) needs to be administered,<br>
then, On 14<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once a week for 11 weeks (2<sup>nd</sup> to <sup>12</sup> week).<br>

<u>2) Fluconazole and Otecon regimen:</u><br>
On 1<sup>st</sup>, 4<sup>th</sup>, and 7<sup>th</sup> day:<br>
Fluconazole 150 mg needs to be administered orally,<br>
then, On 14<sup>th</sup> to 20<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once daily for 7 days,<br>
then, On 28<sup>th</sup> day:<br>
Otecon 150 mg needs to be administered once a week for 11 weeks (4<sup>th</sup> to 14<sup>th</sup> week).<br>
Otecon should be administered orally with food or as directed by the physician.<br>

<b>Contraindications:</b><br>
Oteseconazole is contraindicated in patients with known history of hypersensitivity to it, pregnant and lactating women as well as females of reproductive potential.<br>

<b>Warnings & Precautions:</b><br>
Embryo-Fetal Toxicity:<br>
Based on animal studies, Otes econazole may cause fetal harm. Patients must be advised that Oteseconazole is contraindicated in females of reproductive potential, and in pregnant and lactating women.<br>

<b>Side effects:</b><br>
The most frequently reported side effects were headache and nausea, which were found in less than 2% of patients.<br>
<b>Use in Pregnancy & Lactation:</b><br>
Oteseconazole is contraindicated in females of reproductive potential and in pregnant women. Based on animal studies, Oteseconazole may cause fetal harm when administered to pregnant women. Oteseconazole is contraindicated
Otecon in lactating women. There are no data on the presence of Oteseconazole in human or animal milk or data on the effects of Oteseconazole on milk production. There
Otecon were no reported adverse effects in breastfed infants following maternal exposure to Oteseconazole during lactation.<br>

<b>Use in Children & Adolescents:</b><br>
The safety and effectiveness of Otes econazole have not been established in pre-menarchal paediatric females.<br>

<b>Drug interactions:</b><br>
Oteseconazole is a BCRP (Breast Cancer Resistance Protein) inhibitor. Concomitant use of Oteseconazole with BCRP substrates, may increase the exposure of BCRP substrates (e.g., Rosuvastatin), which
may increase the risk of adverse reactions associated with these drugs.<br>
<b>Overdosage:</b><br>
There is insufficient information about overdosage of Oteseconazole. Overdosage may increase the risk for severe adverse effects.<br>
<b>Storage:</b><br>
Store below 30°C, away from light & in a dry place. Keep all medicines out of the reach of Otecon children.<br>
<b>Packing:</b><br>
Otecon Capsule:<br>
Each box contains 1X10 capsules in Alu-Alu blister pack and an insert.<br><br>

<div class="link-btn" onclick="window.open('https://drive.google.com/file/d/1e5qgsAkBmEP-unNuVbrM7-_wCBT3z6uB/view?usp=sharing', '_blank')">
Otecon PPT.pdf
</div>
<div class="link-btn" onclick="window.open('https://drive.google.com/file/d/1MGhJNslpFvbIvRAyTOUKWGVYC7_ljYpT/view?usp=sharing', '_blank')">
Otecon_ Model Detailing .pdf
</div>

</div>
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Otecon</div></center><!--End Line---->
</body>
</html>
